Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Share on Stocktwits


A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC).

In a July 10 press release, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced it would be presenting preclinical data regarding PMN310 at the AAIC, to be held in Chicago beginning on July 22.

The company, which is focused on "discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases," will present a poster titled "Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight Aβ oligomers while avoiding ARIA-related binding to Aβ deposits in AD patient brains."

In the announcement, ProMIS chief development officer Johanne Kaplan stated that PMN310 "may provide greater therapeutic potency and safety compared to other Aβ-directed antibodies due to its selective targeting of soluble toxic oligomers and the consequently reduced risk of amyloid related imaging abnormalities, or ARIA, allowing for safe administration of higher doses of antibody."

According to the company, the processes leading to development of Alzheimer's disease may not stem from plaques, but rather from toxic amyloid beta (Aβ) oligomers. PMN310, according to ProMIS president and CEO Dr. Elliot Goldstein, "selectively target[s] and neutralize[s] toxic Aβ oligomers with no significant off-target binding to Aβ monomers or plaque."

In the release, Dr. Goldstein expressed the company's belief that "the particular, oligomer selective profile of PMN310 supports a potential best in class profile compared to [other] Aβ therapeutic antibodies currently showing promising results in clinical trials."

The company plans to begin clinical trials for PMN310 in the second half of 2019.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe